Cardiac Dimensions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cardiac Dimensions is a pioneer in percutaneous mitral valve repair, offering a differentiated, early-intervention therapy for functional mitral regurgitation (FMR) in heart failure patients. Its flagship Carillon System is CE Marked and commercially available in Europe and other international markets, supported by a growing body of clinical evidence demonstrating improvements in regurgitation, ventricular remodeling, and quality of life. The company is currently advancing its U.S. regulatory strategy through the EMPOWER pivotal clinical trial. As a private entity, Cardiac Dimensions operates in the competitive structural heart space but is distinguished by its indirect annuloplasty technique, which is less invasive and preserves future treatment options.

Cardiovascular

Technology Platform

Percutaneous, transcatheter indirect mitral annuloplasty via the coronary sinus. Utilizes a dual-anchor nitinol implant to cinch the mitral valve annulus and reduce functional mitral regurgitation.

Opportunities

The large and growing global heart failure population with FMR represents a multi-billion dollar addressable market.

The Carillon system's minimally invasive, early-intervention approach addresses an unmet need for a therapy that treats annular dilation and may slow disease progression, potentially reducing costly hospitalizations.

Positive data from the U.S.

EMPOWER trial could unlock significant value and strategic options.

Risk Factors

The company faces significant regulatory risk dependent on the outcome of the EMPOWER pivotal trial.

It operates in a highly competitive market dominated by large, established players with greater resources.

Achieving commercial adoption and favorable reimbursement, even with approval, requires overcoming entrenched clinical practices and demonstrating clear cost-effectiveness.

Competitive Landscape

Cardiac Dimensions competes in the transcatheter mitral valve repair (TMVR) market, which is dominated by Abbott's MitraClip/TriClip (edge-to-leaflet repair) and Edwards Lifesciences' PASCAL system. Its primary differentiation is its indirect annuloplasty approach via the coronary sinus, targeting the valve annulus rather than the leaflets. Other competitors include direct annuloplasty devices and transcatheter mitral valve replacement (TMVR) systems, though the Carillon's less invasive profile and preservation of future treatment options are key distinguishing factors.

More companies in Small Molecule Drugs →More companies in Germany →